QS Research · Michael Burry's Scion Capital analyst template · 2006
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data
Report price $379.10 (close 2026-11-20)
Conclusion: PASS
Conviction low · base case none · downside -29% · upside +23%
At $379.10 the market pays 5.73x TTM EV/Sales for $1.43B of revenue with -$152.7M TTM EBIT and -$168.7M of free cash flow, and it prices +5.9% annual revenue growth for ten years. No comparable peer multiple sets a base case, so the call rests on the two cases alone. PASS here means 'not a value buy at this price', not a bad business: a growth compounder judged on a deep-value checklist, with ROIC of -804.0% against a 7.0% WACC and an FCF yield of -1.9% leaving too little edge. The downside is -29.2% to $268.30, on -10.0% sales at a compressed EV/Sales of 4.37x (today 5.73x). The upside is +23.2% to $467.21, on +25% sales at today's EV/Sales of 5.73x. There is no base case: no independent multiple from the peer median or the company's own history was available, and a base at today's multiple is today's price by construction. Paulson & Co. at 25.8% of its 13F book and Baker Bros at 5.2% hold against this, but quarter-end marks filed up to 45 days later do not change the arithmetic the price sets.
Key numbers
- Share price: $379.10
- Market cap: $8.81B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $1.43B
- FCF yield: -1.9%
- Price / book: 14.05x
- Revenue growth (latest fiscal year): +432.1%
- ROIC (TTM): -804.0%
- WACC: 7.0%
- Economic profit spread: -811.0 pts
The 15 boxes
- ✓ 1. Long-form business notes
Madrigal, which filed earlier as Synta Pharmaceuticals Corp until 2016-08-01, is a commercial-stage biopharma whose revenue comes from Rezdiffra, its only approved product: FY2025 revenue was $958.4M and TTM to Sep 2026 was $1.43B, up from $0 in FY2022 and FY2023. The FY2020 filing shows a clinical-stage company with resmetirom in Phase 3 and no approved product; by FY2025 it had FDA accelerated approval and an EC conditional marketing authorization, plus a licensed pipeline. It remains loss-making on operating income, net income and operating cash flow in FY2025 and TTM to Sep 2026.
- ✓ 2. Competitive advantage
The advantage is a first-mover regulatory position, not cost, scale or switching costs: Rezdiffra was the first drug approved by both the FDA and the EC for MASH with moderate-to-advanced fibrosis (FDA March 2024, EC CMA August 2025), but Novo's semaglutide is now FDA-approved in MASH and more than 140 MASH programs are in development. The company owns no manufacturing plants and buys all supply from CMOs, so there is no scale-cost moat. The record shows revenue scaling fast ($180.1M FY2024 to $958.4M FY2025 to $1.43B TTM to Sep 2026) while operating income stayed negative (-$300.1M FY2025, -$152.7M TTM), so no margin or return advantage has yet been demonstrated. Durability is conditional: US approval is accelerated and EU approval a CMA, both dependent on confirmatory outcomes trials, and payors/PBMs can steer patients to alternatives.
- ✓ 3. 10-Q takeaways
Q3 2026 product revenue was $431.3 million, up 50% from $287.3 million in Q3 2025, and the quarter produced operating income of $56.0 million and net income of $55.4 million, which the company calls its first profitable quarter. The nine-month picture is still a net loss of $96.9 million on $1,106.9 million of revenue, with SG&A up 44% and cost of sales including a $10.4 million inventory write-down. Cash was $961.8 million at Sep 30, 2026, debt principal was $350.0 million, and the disclosed outlook is trial timing rather than numeric financial guidance.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.